DEF: BioNexus Gene Lab Corp. Sets 2025 Annual Meeting Agenda

BioNexus Gene Lab Corp. announces its 2025 Annual Meeting of Stockholders to vote on director re-elections, a new equity incentive plan, and auditor re-appointment.

Summary

• The Annual Meeting of Stockholders will be held virtually on December 24, 2025, at 9:00 a.m. Eastern Time.
• Stockholders of record as of November 28, 2025, are entitled to vote.
• Key proposals include the re-election of four directors: Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, and Chee Keong Yap.
• Shareholders will vote on the approval of the 2025 Equity Incentive Plan, which authorizes 472,767 shares of Common Stock for issuance and includes an evergreen provision for annual increases of 5% of outstanding shares for nine years (2026-2035).
• The re-appointment of JP CENTURION & PARTNERS PLT as the independent registered public accounting firm for the year ending December 31, 2025, is also on the agenda.
• An Adjournment Proposal will be voted on, allowing for the solicitation of additional proxies if there are insufficient votes for Proposal No. 2 (the 2025 Equity Incentive Plan).
• As of November 28, 2025, there were 2,363,836 shares of Common Stock outstanding.
• Su-Leng Tan Lee, the Chief Executive Officer, received total compensation of $491,126 in fiscal year 2024, including a salary of $490,126 and a bonus of $1,000.

Sentiment

Score: 6

Explanation: The filing outlines routine annual meeting proposals and a new equity incentive plan, which is generally positive for talent retention. However, the need for an adjournment proposal for the equity plan and the significant executive turnover in late 2023 introduce some uncertainty.

Positives

• The proposed 2025 Equity Incentive Plan aims to attract and retain key management, employees, directors, and consultants by offering equity ownership opportunities.
• The Board of Directors has a majority of independent directors (Mr. Chee Keong Yap, Mr. Muhammad Azrul bin Abdul Hamid, and Ms. Jook Yuen Low), aligning with good corporate governance practices.
• The company has established Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors, enhancing specialized oversight.
• A Code of Business Conduct and Ethics, including policies governing insider trading, has been adopted to promote compliance and ethical conduct.

Negatives

• The inclusion of an Adjournment Proposal suggests potential difficulty in securing sufficient votes for the 2025 Equity Incentive Plan (Proposal No. 2).
• There was significant turnover in executive positions in late 2023, with several former officers (Chairman, President, CEO, CFO, COO) resigning or being removed.
• No compensation consultants were used in fiscal year 2024, which might indicate a lack of external benchmarking for executive compensation practices.
• Ms. Jook Yuen Low, a director appointed in November 2024, attended only 1 meeting in fiscal year 2024, which is below the 75% attendance rate for other directors.

Risks

• Failure to approve the 2025 Equity Incentive Plan would mean it will not be in effect, potentially hindering the company's ability to attract and retain key talent through equity compensation.
• There is a risk of insufficient votes for Proposal No. 2 (the 2025 Equity Incentive Plan), which could necessitate an adjournment of the Annual Meeting.
• Broker non-votes are counted as a vote against the 2025 Equity Incentive Plan, increasing the challenge of its approval.
• Forward-looking statements contained in the proxy statement involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially, as detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company intends to adopt policies to ensure future equity grants are made in accordance with applicable laws and best practices regarding the release of material non-public information, contingent on shareholder approval of the 2025 Equity Incentive Plan. The plan itself is designed to provide flexibility in granting equity awards and ensure the company can continue to offer such incentives to eligible recipients.

Management Comments

• "We believe this will enhance accessibility to the Annual Meeting for all of our stockholders, regardless of geographic location." (Regarding the virtual meeting format)
• "The Company believes Mr. Tan is qualified to serve as the Companys Chief Executive Officer and a member of the Board due to his extensive experience with biotech and pharmaceutical companies."
• "The Board has determined that a lead independent director is not necessary at this time." (Due to the current size of the Board and the independent directors' ability to closely monitor activities).
• "The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances."

Industry Context

This filing is a standard proxy statement for an annual meeting, focusing on routine corporate governance matters, executive compensation, and a proposed equity incentive plan. The adoption of an equity incentive plan, particularly with an evergreen provision, is a common practice across many industries, especially in the biotechnology and life sciences sector where BioNexus Gene Lab Corp. operates, to attract, retain, and incentivize key talent by aligning their interests with long-term shareholder value. The virtual meeting format reflects a broader trend towards increased accessibility and efficiency in corporate events.

Comparison to Industry Standards

• The proposed 2025 Equity Incentive Plan, with an evergreen provision of 5% of outstanding shares annually, is a common mechanism for equity compensation in growth-oriented companies, particularly in the biotech sector, to remain competitive in attracting and retaining talent.
• The board composition with a majority of independent directors (3 out of 4) aligns with good corporate governance practices and Nasdaq listing rules, which is a positive indicator compared to global benchmarks.
• The establishment of Audit, Compensation, and Nominating and Corporate Governance Committees, all with independent members, reflects adherence to standard corporate governance structures for publicly traded companies.
• The total compensation for the CEO, Su-Leng Tan Lee, of $491,126 in 2024, should be benchmarked against similar-sized biotech companies to assess its competitiveness and alignment with performance, though specific comparable data is not provided in this filing.

Management Changes

Corporate Governance

Related Party Transactions

• No specific related party transactions are explicitly disclosed beyond the general statement that directors and executive officers have interests in the proposals to the extent of their ownership of shares of common stock.

Stakeholder Impact

• **Shareholders**: Will vote on key governance matters, including director elections, auditor re-appointment, and the equity incentive plan, which could impact future share dilution and management incentives. Their participation in the virtual meeting is facilitated.
• **Employees, Directors, and Consultants**: The 2025 Equity Incentive Plan, if approved, offers opportunities for equity ownership, potentially increasing motivation, retention, and alignment with company performance.
• **Management**: The CEO's compensation is detailed, and the board structure and committees provide oversight. The equity plan provides a tool for incentivizing key personnel.
• **Auditors**: JP CENTURION & PARTNERS PLT is proposed for re-appointment, ensuring continuity of their engagement and financial scrutiny.

Next Steps

• Stockholders are urged to vote on the re-election of directors, approval of the 2025 Equity Incentive Plan, re-appointment of auditors, and the adjournment proposal at the Annual Meeting on December 24, 2025.
• Preliminary voting results will be announced at the Annual Meeting, with final results reported in a Current Report on Form 8-K filed with the SEC.
• If the 2025 Equity Incentive Plan is approved, the Compensation Committee intends to adopt policies for future equity grants.
• Stockholder proposals for the 2026 Annual Meeting must be submitted to the company's corporate Secretary no later than October 1, 2026, to be included in the proxy statement.

Key Dates

Recommendation

The filing is a standard proxy statement for an annual meeting, focusing on corporate governance and a proposed equity incentive plan. It does not contain new financial performance data or strategic announcements that would warrant an immediate 'buy' or 'sell' recommendation. The approval of the equity incentive plan is a positive for talent retention, but the need for an adjournment proposal and past executive turnover introduce some caution. Therefore, a 'hold' recommendation is appropriate as investors await further operational and financial updates.

Keywords

BioNexus Gene Lab Corp, BGLC, Proxy Statement, Annual Meeting, Equity Incentive Plan, Director Election, Corporate Governance, Auditor Re-appointment, Executive Compensation, SEC Filing, Stock Options, Restricted Stock, Virtual Meeting